Saturday 17 October 2026
Export RPID’s income statement to Excel — free account
Rapid Micro Biosystems, Inc.
RPID Healthcare Medical Devices
Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS was flat and free cash flow fell 24.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
0.76
0.09
−10.59%
Follow RPID
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 4 | 2 | 5 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
3.86 | 1.40 | 1.74 | 3.02 | 9.06 | 0.69 | 0.69 | — |
Altman Z-Score |
(8.86) | (6.36) | (3.73) | (1.93) | 4.87 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(22.43) | (11.50) | (2.88) | 1.97 | 11.36 | (10.49) | (23.04) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(39.92) | (3.96) | (4.12) | (4.44) | (16.33) | (1.29) | (1.29) | — |
Beneish M-Score |
(5.06) | — | — | — | — | — | — | — |
P/B ratio |
3.90 | 0.52 | 0.33 | 0.32 | 0.95 | 0.00 | 0.00 | — |
Price to Tangible BV |
3.90 | 0.52 | 0.33 | 0.32 | 0.95 | 0.00 | 0.00 | — |
EV/Sales |
3.28 | (0.18) | (2.06) | (2.90) | 0.75 | (2.79) | (2.79) | — |
EV/EBITDA |
0.00 | 0.11 | 0.87 | 0.82 | 0.00 | 1.65 | 1.65 | — |
EV/Operating CF |
(3.55) | 0.11 | 1.03 | 0.85 | (0.32) | 1.64 | 1.64 | — |
EV/FCF |
(3.45) | 0.11 | 0.99 | 0.76 | (0.30) | 1.59 | 1.59 | — |
Quick Ratio |
2.24 | 3.32 | 5.14 | 5.99 | 10.93 | 3.22 | 1.53 | — |
Current Ratio |
3.31 | 4.61 | 6.34 | 7.27 | 12.01 | 4.00 | 2.24 | — |
Net Debt/EBITDA |
0.44 | 1.09 | 1.72 | 1.68 | 4.23 | 0.70 | (0.31) | — |
Debt/Assets |
25.25% | 0.00% | 0.00% | 3.78% | 0.17% | 35.44% | 56.19% | 0.00% |
Debt/Equity |
0.57 | 0.00 | 0.00 | 0.04 | 0.00 | (0.20) | (0.22) | — |
Asset Turnover |
0.39 | 0.23 | 0.13 | 0.08 | 0.15 | 0.32 | 1.04 | — |
Operating CF/Net income |
0.66 | 0.94 | 0.86 | 0.96 | 0.70 | 0.69 | 0.79 | — |
Capex/Depreciation |
(0.26) | (0.41) | (0.59) | (2.38) | (2.09) | (0.46) | (1.16) | — |
Interest Coverage |
(43.48) | (1,247.97) | — | 35.56 | (18.11) | (8.86) | (7.85) | — |
| (86.82%) | (48.50%) | (37.19%) | (31.58%) | (166.07%) | 43.15% | 25.40% | — | |
| (54.47%) | (38.81%) | (31.41%) | (28.16%) | (50.15%) | (88.94%) | (168.01%) | — | |
ROIC |
(214.45%) | (126.72%) | (136.30%) | (62.99%) | (105.87%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(91.23%) | (62.90%) | (45.92%) | (45.60%) | (36.94%) | (84.28%) | (128.75%) | — |
Average Days of Receivables |
34.06 | 97.84 | 89.67 | 114.38 | 78.63 | 113.24 | 80.18 | — |
Research and Development Expense of Revenue |
40.50% | 52.04% | 56.93% | 75.09% | 42.10% | 40.62% | 32.88% | — |
Selling, General and Administrative Expense of Revenue |
103.72% | 125.53% | 169.89% | 244.05% | 127.88% | 99.14% | 78.55% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
12.01% | 13.81% | 21.09% | 23.46% | 7.93% | 3.32% | 2.86% | — |
Graham Net Nets |
0.15 | 1.48 | 2.43 | 2.16 | 0.94 | (11.82) | (11.82) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 906.71 | 0.00 | — |
Earnings Yield |
(36.90%) | (120.00%) | (134.07%) | (117.21%) | (522.08%) | (508.88%) | (508.88%) | — |
Free Cash Flow Yield |
(24.63%) | (116.06%) | (119.86%) | (126.05%) | (27.63%) | (254.44%) | (254.44%) | — |
Revenue per Share |
0.75 | 0.64 | 0.52 | 0.40 | 1.17 | 44.78 | 47.72 | — |
Operating CF per Share |
(0.70) | (1.01) | (1.05) | (1.38) | (2.78) | (86.34) | (61.12) | — |
Capex per Share |
(0.02) | (0.03) | (0.04) | (0.16) | (0.16) | (1.92) | (4.90) | — |
Free Cash Flow per Share |
(0.71) | (1.04) | (1.09) | (1.54) | (2.94) | (88.26) | (66.02) | — |
Cash per Share |
0.86 | 1.16 | 2.14 | 2.56 | 9.78 | 125.56 | 36.01 | — |
Shareholders Equity per Share |
0.74 | 1.73 | 2.74 | 3.87 | 11.17 | (353.78) | (238.66) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.74 | 1.73 | 2.74 | 3.87 | 11.17 | (353.78) | (238.66) | — |
Free Cash Flow |
(31.91) | (45.52) | (46.93) | (65.29) | (58.16) | (31.69) | (22.84) | — |
Working Capital |
42.68 | 63.35 | 101.43 | 119.53 | 199.96 | 46.61 | 13.08 | — |
Capital Expenditures |
(0.85) | (1.36) | (1.84) | (6.74) | (3.20) | (0.69) | (1.69) | — |
Net Current Asset Value |
19.52 | 58.10 | 94.95 | 112.10 | 197.94 | (134.85) | (90.65) | — |
EV/EBIT |
0.00 | 0.10 | 0.82 | 0.79 | 0.00 | 1.59 | 1.59 | — |
Capex to Sales |
0.03 | 0.05 | 0.08 | 0.39 | 0.14 | 0.04 | 0.10 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.36 | 0.30 | 0.24 | 0.21 | 0.14 | 0.21 | 0.19 | — |
Cash ROIC |
(35.30%) | (36.10%) | (22.34%) | (23.32%) | (14.02%) | 55.47% | 43.67% | — |
Accounts Receivable Turnover |
6.31 | 4.30 | 4.13 | 3.30 | 4.65 | 3.73 | 3.34 | — |
Accounts Payable Turnover |
9.75 | 12.49 | 7.57 | 5.48 | 7.36 | 6.29 | 4.36 | — |
Inventory Turnover |
1.72 | 1.40 | 1.36 | 1.39 | 2.51 | 3.28 | 2.28 | — |
Average Days of Payables |
46.43 | 32.86 | 25.72 | 77.17 | 46.48 | 67.53 | 69.99 | — |
Days of Inventory on Hand |
197.34 | 261.83 | 260.17 | 301.22 | 184.67 | 135.51 | 125.37 | — |
Average Receivables |
5.33 | 6.53 | 5.45 | 5.19 | 5.00 | 4.31 | 4.95 | — |
Average Payables |
3.34 | 2.25 | 3.70 | 4.69 | 4.21 | 3.84 | 3.84 | — |
Average Inventory |
18.90 | 20.08 | 20.57 | 18.43 | 12.32 | 7.36 | 7.36 | — |
Average Assets |
86.51 | 120.81 | 167.05 | 215.91 | 155.58 | 50.84 | 15.84 | — |
Average Common Equity |
54.28 | 96.67 | 141.08 | 192.57 | 46.99 | (104.79) | (104.79) | — |
Columns are period end dates